BPC-157

In rats whose Achilles tendon was surgically transected, animals given BPC-157 showed higher load-to-failure and Young's modulus, higher Achilles functional index scores and smaller macroscopic tendon defects than saline-treated controls through day 14.⁹

In explants and fibroblasts taken from rat Achilles tendon, BPC-157 accelerated fibroblast outgrowth, increased cell survival under hydrogen-peroxide stress and increased transwell migration, while having no direct effect on proliferation by MTT assay.⁸

Across a chick chorioallantoic membrane assay, a human endothelial tube-formation assay and a rat hind-limb ischaemia model, BPC-157 increased vessel density, accelerated laser-Doppler blood-flow recovery and increased vascular VEGFR2 expression; the tube-formation effect was abolished by the endocytosis inhibitor dynasore.³

In rats whose medial collateral ligament was surgically transected, treated animals showed functional, biomechanical, macroscopic and histological improvement relative to controls across a 90-day follow-up.¹⁰

In rabbits with an 8 mm segmental defect in the radius that failed to heal in every saline control over six weeks, BPC-157-treated animals showed radiographic callus and histomorphometric outcomes comparable to autologous bone marrow or cortical graft.¹¹

A formal ADME study in rats and beagle dogs found the intact peptide had an elimination half-life under 30 minutes with linear kinetics, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, and rapid degradation into short fragments and free amino acids entering normal amino acid metabolism.⁴

A 2025 systematic review searching from database inception to June 2024 retrieved 544 articles and included 36 studies, of which 35 were preclinical and one clinical. The authors graded the body of evidence as level IV and level V, and recorded that no clinical safety data were found.¹²

The only human musculoskeletal report is a retrospective single-clinic chart review with telephone follow-up, not a trial: of 16 contactable patients given intra-articular BPC-157 for mixed causes of knee pain, 11 of the 12 who received it alone self-reported improvement. There was no control group, no blinding, no validated outcome instrument and no imaging.¹³

In rats given diclofenac for three days, controls developed gastric, intestinal and liver lesions with raised bilirubin, AST and ALT plus brain oedema and damaged cortical and cerebellar neurons, while treated animals showed markedly reduced lesions on all of these measures.¹⁴

In an uncontrolled, unblinded single-arm pilot, 12 women with interstitial cystitis unresponsive to pentosan polysulfate received peri-lesional injections during cystoscopy and all 12 scored 5/5 on the Global Response Assessment. With no control arm, no blinding and no objective endpoint, this cannot separate a treatment effect from procedural and placebo effects.¹⁵

In cultured rat tendon fibroblasts, microarray identified growth hormone receptor among the most strongly upregulated transcripts after BPC-157 exposure, and adding growth hormone to treated cells increased proliferation and JAK2 activation. This was a receptor-expression effect in culture, not a measurement of growth hormone secretion in a living animal.⁷

In rats subjected to 20 minutes of bilateral carotid clamping, BPC-157 applied to the operative field at reperfusion was associated with reduced hippocampal neuronal damage and recovery on Morris water maze and beam-walking tests at 24 and 72 hours, alongside elevated hippocampal Egr1, Akt1, Vegfr2 and Nos3 mRNA.⁶